Loading stock data…
ICU
$2.78-0.12 (-4.14%)
After Hours$2.72-0.06 (-2.16%)· Last close Jun 9
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SeaStar Medical Holding Corporation in the Healthcare sector is trading at $2.78. Wall Street consensus targets $10.00 (2 analysts), implying a +259.7% move over the next 12 months. The stock is currently near its 52-week low of $2.07, remaining 35.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +259.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 14) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.78
Potential Downside
0%
Whystock Fair Value$2.78
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-162.67%
Volume
Today's trading volume
103,913
Recent News
SeaStar Medical Holding Corporation Q2 2026 Earnings Call Summary
Moby summary of SeaStar Medical Holding Corporation's Q2 2026 earnings call
SeaStar Medical Holding Corp (ICU) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
SeaStar Medical Holding Corp (ICU) reports a 69% increase in Quelimmune net revenue and significant trial advancements, despite facing operational and market entry hurdles.
SeaStar Medical (ICU) Q1 2026 Earnings Transcript
Eric Schlorff: Thank you. With our growing presence and the continued adoption of Quellimmune in the pediatric AKI market, we believe we are on track to meet our net revenue goal of approximately $2 million for the year. More importantly, we are setting the stage for our next and potentially far larger market opportunity in the adult AKI market.
Full Transcript: SeaStar Medical Holding Q1 2026 Earnings Call
On Wednesday, SeaStar Medical Holding (NASDAQ:ICU) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://edge.media-server.com/mmc/p/d4of9ds2/ Summary SeaStar Medical Holding reported a nearly 70% increase in Quellimmune net revenue for the first quarter
SeaStar Medical Holding Corp (ICU) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
SeaStar Medical Holding Corp (ICU) reports significant revenue growth and customer base expansion, while navigating financial hurdles and regulatory challenges in its Q4 2025 earnings call.